No holiday gift for GSK: FDA sends long-acting HIV injectable back to work

HIV patients hunting for relief from the burden of daily pills should wait longer. Saturday, GlaxoSmithKline's ViiV Healthcare declared that the FDA had rejected its long-acting HIV injection, known underneath of the working title Cabenuva. The statement is thin on details, noting with the exception that large response letter pertains to chemistry manufacturing and controls … Continue reading No holiday gift for GSK: FDA sends long-acting HIV injectable back to work